[1]夏劲松.反义显像技术的研究进展[J].国际放射医学核医学杂志,2001,25(2):62-65.
 XIA Jin-song.Progression of antisense oligonucleotides for non-invasive imaging in vivo[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(2):62-65.
点击复制

反义显像技术的研究进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第2期
页码:
62-65
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Progression of antisense oligonucleotides for non-invasive imaging in vivo
作者:
夏劲松
430030 湖北武汉, 华中科技大学同济医学院附属同济医院核医学科
Author(s):
XIA Jin-song
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical University, Hubei Wuhan 430030, China
关键词:
反义显像受体脂质体反义寡核苷酸
Keywords:
antisense imagingreceptorliposomesantisense oligonucleotide
分类号:
R817.4
摘要:
反义显像是利用放射性核素标记的反义寡核苷酸,通过体内核酸杂交而显示目的基因表达的一种显像方法,具有设计简便、合成简易、安全性高、免疫原性低等特点。成功的反义显像要求反义寡核苷酸易被细胞摄取、耐核酸酶、杂交稳定、标记简单。脂质体、受体等介导的反义RNA转移,反义寡核苷酸的化学修饰以及标记方法的改进将大大加快反义显像的临床应用。
Abstract:
Antisense imaging is widely used as a novel method to assess gene expression by nucleic acid hybridization with anisense oligonucleotide labelled by radionucide in vivo, with advantages of easy controlling for synthesis, high reliability and low immunogenicity. The requirements for ideal antisense imaging include easy intakeing by cells, convenient labelling, stable hybridization and the tolerance against nuclease. The progression in antisense imaging, such as the transfer of antisense RN A mediated by liposomes or receptor, chemical modification of antisense oligonucleotide and the improvement of labelling, will greatly improve the clinical application of antisense imaging.

参考文献/References:

[1] Myers KJ,Dean NM.Sensible use of antisense:how to use oligonucleotides as research tools[J].Trends Phimacol Sci,2000,21:19-23.
[2] Poston RS,Tran KP,Mann M J,et al.Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotide[J].J Heart Lung Transplant,1998,17:349-355.
[3] Hnatowich DJ.Changing focus:applying antisense to nuclear medicine imaging[J].Mol Med Today,1999,5:151.
[4] ManiS,Gu Y,Wadler S,et al.Antisense therapeutics in oncology:points to consider in their clinical evaluation[J].Antisense Nucleic Acid Drug Dev,1999,9:543-547.
[5] Asaoka K,Tadam,Sawamura Y,et al.Dependence of efficient adenviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus recepter[J].J Neursurg,2000,92:1002-1008.
[6] Malatynska E,Matheson GK,Goldenberg R,et al.Effects of treatment with GABA(A) receptor subunit antisense oligodeoxynucleotides on GABA-stimulated 36C1-infiux in the rat cerebral cortex[J].Neurochem Int,2000,36:45-54.
[7] Cooper SR,Taylor JK,Miraglia LJ,et al.Pharmacology of antisense oligonucleotide inhiibitors of protein expression[J].Pharmacol Ther,1999,82.427-435.
[8] Hogrefe RI.An antisense oligonucleotide primer[J].Antisense Nucleic Acid Drug Dev,1999,9:351-357.
[9] Gauchez AS,Du Moulinet D’Hardemare A,Lunardi J,et al.Potential use of radiolabeled antisense oligonucleotides in oncology[J].Anticancer Res,1999,19:4989-4997.
[10] Alt M,Eisenhardt S,Serwe M,et al.Comparative inhibitory potential of diffently modified antisense oligodeoxynucleotides on hepatitis C virus translation[J].Eur J Clin Invest.1999,29:868-876.
[11] Hnatowich DJ.Antisense and nuclear medicine[J].J Nucl Med,1999,40(4):693-703.
[12] Tavitian B.In vivo antisense imaging[J].Q J Nucl Med,2000,44:236-255.
[13] Dewanjee MK,Vargas R,Ghafouripour AK,et al.Kinetics of intracellular hybridization of c-myc mRNA oncogene with 111In labeled antisense deoxyoligonucleotide probes in leukemic cells[J].J Nucl Med,1994,34:224.
[14] Lu Xiao-ming,Alan J,Fischman,et al.Antisense DNA delivery in vivo:Liver targeting by receptor-mediated uptake[J].J Nucl Med,1994,35:269-275.
[15] Dewanjee M K,Ghafouripour AK,Kapadvanjwala M,et al.Radiolabeled antisense oligodeoxynucleotides:in vitro and in vivo applications[J].JClin Immunoassay,1993,16:276-289.
[16] HnatowichDJ,Winnard P,Virzi F,et al.Technetium-99m labeling of DN A oligonucleotides[J].J Nud Mecl,1995,36:2306-2314.
[17] Hnatowich DJ.Antisense imaging:Where are we now?[J].Cancer Biother Radiopharm,2000,15:447-457.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
 Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
 Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
 Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
 Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
 Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
 Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
 ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
 LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
 YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
 BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]

备注/Memo

备注/Memo:
收稿日期:2000/6/29。
作者简介:夏劲松(1973-),男,湖北通山人,华中科技大学同济医学院博士研究生。主要研究方向:特异性靶向药物的研制和肿瘤核医学。
更新日期/Last Update: 1900-01-01